CSPC Pharmaceutical Group (01093.HK): Results from the Phase I/II Clinical Study of the Anti-PD-1/IL-15 Bifunctional Fusion Protein SYS6090 (JMT108) as Monotherapy for Advanced Solid Tumors Presented as a Rapid Oral Presentation at the 2026 ESMO Congress

Zhitong Finance APP news, CSPC Pharmaceutical Group (01093.HK) announced that the results of the first-in-human Phase I/II clinical study (the study) of SYS6090 (JMT108) (the product), a bifunctional fusion protein targeting programmed death receptor 1 (PD-1)/interleukin-15 (IL-15) developed by the Group, in patients with advanced solid tumors were presented on October 25, 2026 in a rapid oral presentation (number: 1009RO) at the 2026 European Society for Medical Oncology (ESMO) Annual Congress.